Abstract: The invention relates to a conduit insert (1) comprising an adapter (10) having a liquid inlet (11) and a liquid outlet (12) and between them a chamber (13) having a first planar end wall into which the liquid inlet (11) opens, and an opposite second planar end wall, which is parallel to the first end wall and into which the liquid outlet (12) opens, and an access opening (16) extending from the first planar end wall of the chamber (13) to the second planar end wall of the chamber. A conduit access means (20) is slidable into and extractable out of the chamber (13) via the access opening (16) and has a first planar end face and an opposite second planar end face which is parallel to the first planar end face.

Abstract: Anthracycline derivatives are suitable for use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthracycline derivatives can also be used together with a drug delivery system, in particular including a two-step targeting strategy, for treating solid and disseminated tumors. These drug delivery system can advantageously be used for treatment and diagnosis of breast cancer.

Abstract: Anthracycline derivatives are suitable for use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthracycline derivatives can also be used together with a drug delivery system, in particular including a two-step targeting strategy, for treating solid and disseminated tumours. These drug delivery system can advantageously be used for treatment and diagnosis of breast cancer.

Abstract: The present invention relates to a drug delivery system with two-step targeting, which comprises a combination: (a) a lipid carrier provided with cell targeting agent(s) to target the drug delivery system to specific cells or tissues; and (b) a drug enclosed in said lipid carrier and provided with a DNA targeting agent to target the drug to the nuclei of specific target cells. Furthermore, the invention relates to a method of cancer therapy in which the above drug delivery system is administered to a cancer patient. The goal is to treat or analyse both large tumour masses as well as small tumour cell clusters and single spread tumour cells. According to the invention, drug uptake in tumours will be markedly increased at the same time as the interaction of the drug with healthy organs and tissues can be minimized. The invention gives potential to convert palliative into curative treatment.